Araclon archivos

Attendance at AD/PD 2025

24 de April de 2025 by Araclon

Araclon Biotech, a Grifols company, presented the results of its clinical validation study of ABtest-MS in populations with mild cognitive impairment, and of its ABvac40 vaccine regarding its impact on the progression of Alzheimer’s disease (AD) and Cerebral Amyloid Angiopathy (CAA) at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD … Read more

ADPD 2025

18 de March de 202512 de March de 2025 by Araclon

We are thrilled to announce our participation in the upcoming AD/PD 2025 Congress in Vienna (April 1-5) // Join us at AD/PD2025 Congress in Vienna (April 1-5) This hybrid event will unite experts and leaders from the health, neuroscience, and biotechnology sectors to discuss the latest advancements in neurodegenerative diseases such as Alzheimer’s and Parkinson’s, … Read more